title: Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
abstract: OBJECTIVE
  In hepatitis C virus (HCV)-infected patients receiving pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy, anemia is a well-known side effect. The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia.
  
  
  METHODS
  In this multicenter, observational, 8-wk study, laboratory parameters were measured weekly for 8 wk or until early withdrawal. Primary endpoints included changes in Hb and serum erythropoietin (sEPO) from baseline to week 8; other measures were changes in reticulocytes and RBV dose. The predictive value of baseline factors for maximum Hb decline was assessed.
  
  
  RESULTS
  In the 97 evaluable patients, mean Hb decreased from 14.4 +/- 1.4 g/dl (baseline) to 11.9 +/- 1.3 g/dl (week 8). Twenty-one percent of patients withdrew before week 8. The estimated erythropoietic response was lower than that seen in two historic control populations of iron deficiency anemia patients. Mean RBV dose decreased from 986 +/- 190 mg/day (baseline) to 913 +/- 228 mg/day (week 8). Fifty-seven out of 77 (74%) patients who completed the study maintained their initial prescribed RBV dose. Patients maintained on the initial dose of RBV who had a higher baseline Hb and viral load showed a trend toward larger Hb declines. Platelets and white blood cells (WBCs) also declined during the study.
  
  
  CONCLUSIONS
  HCV-infected patients receiving PEG-IFN/RBV therapy have reductions in Hb, platelets, and WBCs, possibly due to bone marrow suppression. They also have diminished endogenous sEPO production for their degree of anemia.
authors.affiliation: Division of Transplantation Medicine, Mayo Clinic Hospital, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA.
authors.forename: Vijayan
authors.initials: V
authors.lastname: Balan
authors.forename: David
authors.initials: D
authors.lastname: Schwartz
authors.forename: George Y
authors.initials: GY
authors.lastname: Wu
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Muir
authors.forename: Reem
authors.initials: R
authors.lastname: Ghalib
authors.forename: John
authors.initials: J
authors.lastname: Jackson
authors.forename: Emmet B
authors.initials: EB
authors.lastname: Keeffe
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Rossaro
authors.forename: Alfreda
authors.initials: A
authors.lastname: Burnett
authors.forename: Betty L
authors.initials: BL
authors.lastname: Goon
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Bowers
authors.forename: Gerhard J
authors.initials: GJ
authors.lastname: Leitz
mesh_terms: D000740:Anemia / Q000097:blood* / Q000139:chemically induced; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b